A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia) Clinical Trial

Official title:

A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02439359
• Other study ID #: CF 301-101
• Status: Completed
• Phase: Phase 1
• Start date: May 2015
• Est. completion date: December 2015

Study information

• Verified date: December 2016
• Source: ContraFect
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Be a healthy male of any race or ethnicity, at least 18 years of age and no more than 55 years of age, inclusively, OR

2. Be a healthy female of any race or ethnicity of non-childbearing potential between 18 and 55 years of age, inclusive. OR

3. Be a healthy non-pregnant, non-lactating female of any race or ethnicity of childbearing potential between 18 and 55 years of age,

4. Contraception in use for at least 60 days prior to the Screening visit,

5. Have a body mass index (BMI) between 18.5 and 32 kg/m2, inclusive

6. Have no significant diseases in the opinion of the Investigator in the medical history or clinically significant findings on physical examination or clinical laboratory evaluations.

Exclusion Criteria:

1. Any disease or condition in the opinion of the Investigator that might compromise the cardiovascular, hematologic, renal, hepatic, pulmonary (including chronic asthma), endocrine (eg, diabetes), central nervous, or gastrointestinal (including an ulcer) systems.

2. The presence of clinically significant laboratory values that are out of the normal range.

• Subjects with an aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), alkaline phosphatase, bilirubin, blood urea nitrogen (BUN), creatinine, prothrombin time (PT), or activated partial thromboplastin time (aPTT) > 5% above the upper limit of normal, or hemoglobin or hematocrit level < 5% below the lower limit of normal may not be enrolled.

3. A history of alcoholism or drug addiction, or illicit drug use within the past 2 years, or positive results from a urine screen for substances of abuse.

4. Has smoked within 28 days prior to receiving study drug or has a positive urine test for cotinine.

5. A history of serious mental illness.

6. A history of difficulty donating blood or inadequate venous access.

7. The donation of blood or plasma within 28 days prior to receiving study drug.

8. A positive hepatitis screen that tests for both hepatitis B surface antigen (HBsAg) and antibody to hepatitis C virus (HCVAb).

9. A positive test result for human immunodeficiency virus (HIV) antibody by enzyme immunoassay, which is confirmed by Western blot.

10. Use of an investigational drug or product, or participation in a drug study within a period of 28 days prior to receiving study drug (for investigational drugs with an elimination half-life greater than 10 days, this will be extended to 60 days).

11. Use of any prescription or over-the-counter (OTC) drug therapy, including herbal, homeopathic, vitamins, minerals and nutritional supplements, within 2 weeks prior to receiving the study drug contraceptives in women of childbearing potential is allowed during the study.

• If a subject taking prescription drug therapy for chronic diseases, but that prescription is stopped in order to qualify for the study, the subject should not be enrolled in the study.

12. Use of any drug therapy (ie, prescription drugs, over-the counter products, herbal and vitamin products) known to induce or inhibit cytochrome P450 hepatic enzymes responsible for drug metabolism within 28 days prior to receiving study drug or during the study.

Related Conditions & MeSH terms

• Bacteremia
• Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)

Intervention

Drug:
• CF-301
Dose escalation
• Placebo

Locations

Country	Name	City	State
United States	Cf 301-105	Omaha	Nebraska

Sponsors (1)

Lead Sponsor	Collaborator
ContraFect

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability as measured by AE's	Safety and tolerability will be assessed by monitoring AEs and performing physical/clinical examinations.	up to 8 months